Conducting collaborative research locally, nationally and globally.
You are viewing an old version of this page. View the current version.
Compare with Current View Page History
« Previous Version 29 Next »
Best, L.M., Hendershot, C.S., Buckman, J.F., Jagasar, S., McPhee, M.D., Muzumdar, N., Tyndale, R.F., Houle, S., Logan, R., Sanches, M., Kish, S.J., Le Foll, B. & Boileau, I. 2023. Association between Fatty Acid Amide Hydrolase and Alcohol Response Phenotypes: A Positron Emission Tomography Imaging Study with [(11)C]Curb in Heavy-Drinking Youth. Biol Psychiatry, 94(5):405-415.
Bourgault, Z., Matheson, J. & Le Foll, B. 2023. Genetic Variation and Acute Responses to Cannabis. In: Martin, C.R., Patel, V.B. & Preedy, V.R. (eds.). Cannabis Use, Neurobiology, Psychology, and Treatment: Academic Press.
Butler, K., Le Foll, B. & Di Ciano, P. 2023. The Role of Dopamine D3 Receptors in Tobacco Use Disorder: A Synthesis of the Preclinical and Clinical Literature. Curr Top Behav Neurosci, 60:203-28.
Bastien, G., McAnulty, C., Ledjiar, O., Socias, M.E., Le Foll, B., Lim, R., Hassan, A.N., Brissette, S., Marsan, S., Talbot, A., Jutras-Aswad, D. & Optima Research Group within the Canadian Research Initiative in Substance Misuse 2023. Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial. Can J Psychiatry, 68(8):572-585.
Di Ciano, P., Brands, B., Fares, A., Wright, M., Stoduto, G., Byrne, P., McGrath, M., Hasan, O.S.M., Le Foll, B. & Wickens, C.M. 2023. The Utility of THC Cutoff Levels in Blood and Saliva for Detection of Impaired Driving. Cannabis Cannabinoid Res, 8(3):408-413.
Elkrief, L., Bastien, G., McAnulty, C., Bakouni, H., Hébert, F.-O., Socias, M.E., Le Foll, B., Lim, R., Ledjiar, O., Marsan, S., Brissette, S., Jutras-Aswad, D., Bornemisza, S., Bouman, H., Elliott, S., Evans, L., Ghosh, M., Gursky, L., Vezina, L., Wild, C., Yu, A., Ahamad, K., Bach, P., Brar, R., Fairbairn, N., Fairgrieve, C., Habibian, S., Klaire, S., MacDonald, S., McLean, M., Nolan, S.C., Prinsloo, G., Sutherland, C., Wood, E., Bozinoff, N., Fischer, B., Franklin, M., Hassan, A., Kahana, D., Lagzdins, D., Marsh, D., Rehm, J., Barbeau, D., Bruneau, J., Maynard, S., Talbot, A. & Juteau, L.-C. 2023. Differential Effect of Cannabis Use on Opioid Agonist Treatment Outcomes: Exploratory Analyses from the Optima Study. Journal of Substance Use and Addiction Treatment, 149:209031.
Enns, B., Krebs, E., Whitehurst, D.G.T., Jutras-Aswad, D., Le Foll, B., Socias, M.E., Nosyk, B. & Optima Research Group within the Canadian Research Initiative in Substance Misuse 2023. Cost-Effectiveness of Flexible Take-Home Buprenorphine-Naloxone Versus Methadone for Treatment of Prescription-Type Opioid Use Disorder. Drug Alcohol Depend, 247:109893.
Elsaid, S., Truong, P., Sailasuta, N. & Le Foll, B. 2023. Evaluating Back-to-Back and Day-to-Day Reproducibility of Cortical Gaba+ Measurements Using Proton Magnetic Resonance Spectroscopy ((1)H Mrs). Int J Mol Sci, 24(9).
Gewandter, J.S., Edwards, R.R., Hill, K.P., Wasan, A.D., Hooker, J.E., Lape, E.C., Besharat, S., Cowan, P., Le Foll, B., Ditre, J.W. & Freeman, R. 2023. Cannabinoid Therapy: Attitudes and Experiences of People with Chronic Pain. Clin J Pain, 39(6):249-258.
Hassan, A.N., Agabani, Z., Ahmed, F., Shapiro, B. & Le Foll, B. 2023. The Impact of Religiosity/Spirituality on Slowing the Progression of Substance Use: Based on the National Epidemiological Survey of Alcohol and Related Conditions (Nesarc-Iii). Int J Soc Psychiatry, 69(6):1399-1408.
Hassan, A.N., Bozinoff, N., Jutras-Aswad, D., Socias, M.E., Stewart, S.H., Lim, R., Le Foll, B. & Optima Research Group 2023. Patient Satisfaction with Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results from a Pragmatic Randomized Controlled Clinical Trial. J Addict Med, 17(1):e49-e56.
Hauck, T.S., Ladha, K.S., Le Foll, B., Wijeysundera, D.N. & Kurdyak, P. 2023. Postoperative Buprenorphine Continuation in Stabilized Buprenorphine Patients: A Population Cohort Study. Addiction, 118(10):1953-1964.
Kim, S., Rajack, N., Mondoux, S.E., Tardelli, V.S., Kolla, N.J. & Le Foll, B. 2023. The Covid-19 Impact and Characterization on Substance Use-Related Emergency Department Visits for Adolescents and Young Adults in Canada: Practical Implications. J Eval Clin Pract, 29(3):447-458.
Magarbeh, L., Gorbovskaya, I., Wells, R., Jhirad, R., Le Foll, B. & Muller, D.J. 2023. Pharmacogenetics of Lethal Opioid Overdose: Review of Current Evidence and Preliminary Results from a Pilot Study. J Pers Med, 13(6).
Matheson, J. & Le Foll, B. 2023. Acute and Chronic Impact of Cannabis on Human Cognition. In: Martin, C.R., Patel, V.B. & Preedy, V.R. (eds.). Cannabis Use, Neurobiology, Psychology, and Treatment: Academic Press.
Matheson, J. & Le Foll, B. 2023. Impacts of Recreational Cannabis Legalization on Use and Harms: A Narrative Review of Sex/Gender Differences. Front Psychiatry, 14:1127660.
Mocanu, V., Bozinoff, N., Wood, E., Jutras-Aswad, D., Le Foll, B., Lim, R., Cheol Choi, J., Yin Mok, W., Eugenia Socias, M. & Optima Research Group within the Canadian Research Initiative in Substance Misuse 2023. Opioid Agonist Therapy Switching among Individuals with Prescription-Type Opioid Use Disorder: Secondary Analysis of a Pragmatic Randomized Trial. Drug Alcohol Depend, 248:109932.
Ragheb, H., Ahmad, S., Uddin, S., Le Foll, B. & Hassan, A.N. 2023. The Prevalence and Treatment Utilization of Substance Use Disorders among Muslims in the United States: A National Epidemiological Survey. Am J Addict, 32(5):497-505.
Russell, C., Law, J., Imtiaz, S., Rehm, J., Le Foll, B. & Ali, F. 2023. The Impact of Methamphetamine Use on Medications for Opioid Use Disorder (Moud) Treatment Retention: A Scoping Review. Addict Sci Clin Pract, 18(1):48.
Sokoloff, P. & Le Foll, B. 2023. A Historical Perspective on the Dopamine D3 Receptor. In: Boileau, I. & Collo, G. (eds.). Therapeutic Applications of Dopamine D3 Receptor Function: New Insight after 30 Years of Research. Cham: Springer International Publishing.
Tang, V.M., Goud, R., Zawertailo, L., Selby, P., Coroiu, A., Sloan, M.E., Chenoweth, M.J., Buchman, D., Ibrahim, C., Blumberger, D.M. & Le Foll, B. 2023. Repetitive Transcranial Magnetic Stimulation for Smoking Cessation: Next Steps for Translation and Implementation into Clinical Practice. Psychiatry Res, 326:115340.
Tang, V.M., Yu, D., Weissman, C.R., Jones, B.D.M., Wang, G., Sloan, M.E., Blumberger, D.M., Daskalakis, Z.J., Le Foll, B. & Voineskos, D. 2023. Treatment Outcomes in Major Depressive Disorder in Patients with Comorbid Alcohol Use Disorder: A Star*D Analysis. J Affect Disord, 339:691-697.
Tardelli, V.S., Johnstone, S., Xu, B., Kim, S., H, K.K., Gratzer, D., George, T.P., Le Foll, B. & Castle, D.J. 2023. Marked Increase in Amphetamine-Related Emergency Department Visits and Inpatient Admissions in Toronto, Canada, 2014-2021. Can J Psychiatry, 68(4):249-256.
Wang, R., Trigo, J.M. & Le Foll, B. 2023. Effects of Sub-Chronic Nabiximols on Biological Markers of Individuals Undergoing a Clinical Trial for the Treatment of Cannabis Use Disorder. Am J Transl Res, 15(8):5228-5238.
Whitehurst, D.G.T., Mah, C., Krebs, E., Enns, B., Socias, M.E., Jutras-Aswad, D., Le Foll, B., Nosyk, B. & Optima Research Group within the Canadian Research Initiative in Substance Misuse 2023. Sensitivity to Change of Generic Preference-Based Instruments (Eq-5d-3l, Eq-5d-5l, and Hui3) in the Context of Treatment for People with Prescription-Type Opioid Use Disorder in Canada. Qual Life Res, 32(8):2209-2221.
Xiao, K.B., Grennell, E., Ngoy, A., George, T.P., Le Foll, B., Hendershot, C.S. & Sloan, M.E. 2023. Cannabis Self-Administration in the Human Laboratory: A Scoping Review of Ad Libitum Studies. Psychopharmacology (Berl), 240(7):1393–1415.
Zhang, H., Gilbert, E., Hussain, S., Veldhuizen, S., Le Foll, B., Selby, P. & Zawertailo, L. 2023. Effectiveness of Bupropion and Varenicline for Smokers with Baseline Depressive Symptoms. Nicotine Tob Res, 25(5):937-944.